Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Company profile
Ticker
TYME
Exchange
Website
CEO
Steve Hoffman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GLOBAL GROUP ENTERPRISES CORP.
SEC CIK
Corporate docs
Subsidiaries
Tyme, Inc. ...
TYME stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
30 Sep 22
EFFECT
Notice of effectiveness
22 Sep 22
EFFECT
Notice of effectiveness
22 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
POS AM
Prospectus update (post-effective amendment)
16 Sep 22
POS AM
Prospectus update (post-effective amendment)
16 Sep 22
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.42 mm | 6.42 mm | 6.42 mm | 6.42 mm | 6.42 mm | 6.42 mm |
| Cash burn (monthly) | 2.44 mm | 2.50 mm | 2.20 mm | 2.12 mm | 1.59 mm | 1.68 mm |
| Cash used (since last report) | 17.63 mm | 18.08 mm | 15.91 mm | 15.33 mm | 11.51 mm | 12.17 mm |
| Cash remaining | -11.22 mm | -11.67 mm | -9.49 mm | -8.91 mm | -5.10 mm | -5.75 mm |
| Runway (months of cash) | -4.6 | -4.7 | -4.3 | -4.2 | -3.2 | -3.4 |
Institutional ownership, Q2 2022
6.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 55 |
| Opened positions | 12 |
| Closed positions | 12 |
| Increased positions | 11 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 3.24 mm |
| Total shares | 10.89 mm |
| Total puts | 52.40 k |
| Total calls | 147.00 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 3.97 mm | $1.11 mm |
| BLK Blackrock | 1.93 mm | $540.00 k |
| Renaissance Technologies | 1.23 mm | $343.00 k |
| Geode Capital Management | 800.67 k | $224.00 k |
| Pathstone Family Office | 500.11 k | $140.00 k |
| HighTower Advisors | 342.00 k | $96.00 k |
| STT State Street | 295.17 k | $83.00 k |
| Millennium Management | 213.53 k | $60.00 k |
| NTRS Northern Trust | 185.61 k | $52.00 k |
| MS Morgan Stanley | 171.71 k | $49.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 0.31 | 88,000 | 27.28 k | 0 |
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 1.1 | 88,000 | 96.80 k | 0 |
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 1.22 | 65,000 | 79.30 k | 0 |
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 1.18 | 50,000 | 59.00 k | 0 |
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 2.33 | 50,000 | 116.50 k | 0 |
| 16 Sep 22 | Donald W DeGolyer | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 2.9 | 100,000 | 290.00 k | 0 |
| 16 Sep 22 | Gerald H Sokol | Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,865 | 0.00 | 0 |
| 16 Sep 22 | Gerald H Sokol | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 0.31 | 88,000 | 27.28 k | 0 |
| 16 Sep 22 | Gerald H Sokol | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 1.1 | 88,000 | 96.80 k | 0 |
| 16 Sep 22 | Gerald H Sokol | Director Stock Option - Option to buy Common Stock | Sale back to company | Dispose D | No | No | 1.22 | 65,000 | 79.30 k | 0 |